181 related articles for article (PubMed ID: 21410668)
1. Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Tampucci S; Mailland F
Br J Dermatol; 2011 Jul; 165(1):99-105. PubMed ID: 21410668
[TBL] [Abstract][Full Text] [Related]
2. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activity, experimental infections and nail permeation of an innovative ciclopirox nail lacquer based on a water-soluble biopolymer.
Togni G; Mailland F
J Drugs Dermatol; 2010 May; 9(5):525-30. PubMed ID: 20480796
[TBL] [Abstract][Full Text] [Related]
4. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimycotic activity and nail permeation models of a piroctone olamine (octopirox) containing transungual water soluble technology.
Dubini F; Bellotti MG; Frangi A; Monti D; Saccomani L
Arzneimittelforschung; 2005; 55(8):478-83. PubMed ID: 16149717
[TBL] [Abstract][Full Text] [Related]
6. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
Bohn M; Kraemer K
J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
[TBL] [Abstract][Full Text] [Related]
7. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
[TBL] [Abstract][Full Text] [Related]
8. A-Detail fact sheet (Canada). Ciclopirox 8% nail lacquer (Penlac).
Skin Therapy Lett; 2005 Dec-2006 Jan; 10(10):suppl 1 p.. PubMed ID: 16518906
[No Abstract] [Full Text] [Related]
9. Ciclopirox nail lacquer topical solution 8%.
Gupta AK
Skin Therapy Lett; 2000; 6(1):1-5. PubMed ID: 11027420
[TBL] [Abstract][Full Text] [Related]
10. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
Ceschin-Roques CG; Hänel H; Pruja-Bougaret SM; Luc J; Vandermander J; Michel G
Skin Pharmacol; 1991; 4(2):89-94. PubMed ID: 1831626
[TBL] [Abstract][Full Text] [Related]
11. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
Traynor MJ; Turner RB; Evans CR; Khengar RH; Jones SA; Brown MB
J Pharm Pharmacol; 2010 Jun; 62(6):730-7. PubMed ID: 20636860
[TBL] [Abstract][Full Text] [Related]
12. Potential of Naftifine Application for Transungual Delivery.
Šveikauskaitė I; Briedis V
Molecules; 2020 Jul; 25(13):. PubMed ID: 32635240
[TBL] [Abstract][Full Text] [Related]
13. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Saettone MF; Mailland F
Drug Dev Ind Pharm; 2005 Jan; 31(1):11-7. PubMed ID: 15704853
[TBL] [Abstract][Full Text] [Related]
14. An investigation into keratinolytic enzymes to enhance ungual drug delivery.
Mohorcic M; Torkar A; Friedrich J; Kristl J; Murdan S
Int J Pharm; 2007 Mar; 332(1-2):196-201. PubMed ID: 17097244
[TBL] [Abstract][Full Text] [Related]
15. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
16. Ciclopirox delivery into the human nail plate.
Hui X; Wester RC; Barbadillo S; Lee C; Patel B; Wortzmman M; Gans EH; Maibach HI
J Pharm Sci; 2004 Oct; 93(10):2545-8. PubMed ID: 15349963
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Seebacher C; Nietsch KH; Ulbricht HM
Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
[TBL] [Abstract][Full Text] [Related]
18. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
Avner S; Nir N; Henri T
J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
20. Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.
Vejnovic I; Huonder C; Betz G
Int J Pharm; 2010 Sep; 397(1-2):67-76. PubMed ID: 20620203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
